2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Sermonix Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Lasofoxifene and abemaciclib (VERZENIO (R)). - Metastatic Breast Cancer | Phase 2 | Completed | Sermonix Pharmaceuticals Inc. | 29 | 2020-09-29 | 2025-02-13 |
| Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Lasofoxifene, Fulvestrant - Locally Advanced or Metastatic Breast Cancer | Phase 2 | Completed | Sermonix Pharmaceuticals Inc. | 100 | 2019-09-20 | 2026-01-28 |
Breast Neoplasms (2)
Lasofoxifene (2) · Fulvestrant (1) · abemaciclib (1)
United States (2) · Canada (1) · Israel (1)